MMI Completes World’s First Robotic Preclinical Study in Neurosurgery with Symani® Surgical System

First-of-its-kind procedure a breakthrough in expanding robotic capability to complex neurosurgical care

MMI (Medical Microinstruments, Inc.), a robotics company dedicated to increasing treatment options and improving clinical outcomes for patients with complex conditions, today announced the completion of a preclinical study that demonstrated the feasibility of the Symani® Surgical System in neurosurgical procedures. Adnan Siddiqui, M.D., Ph.D., Chief Executive Officer and Chief Medical Officer of the Jacobs Institute and Vice Chair and Professor of Neurosurgery in the Jacobs School of Medicine and Biomedical Sciences, successfully repaired a blood vessel in the brain in an animal model using the Symani Surgical System, the first such robotic-assisted microsurgery demonstration in the brain.

“Dr. Siddiqui’s breakthrough demonstration showed the benefits of robotic precision and control when operating on brain tissue,” said Mark Toland, CEO of MMI. “The robotic platform allowed him to perform extremely delicate maneuvers deep in the skull cavity that would not have been possible with the human hand alone. The success of this procedure opens the possibility of expanding Symani’s reach into neurosurgery, a field of medicine that involves the most fragile anatomy and has yet to benefit from robotic-assisted microsurgical capabilities.”

The study aimed to both collect feedback on Symani from a highly experienced neurosurgeon and assess the feasibility of the platform as a tool to treat neurological conditions. It was performed at the Jacobs Institute, a nonprofit medical device innovation center located in Buffalo, N.Y., which aims to accelerate the development of next-generation technologies in vascular medicine.

“Symani offered added control that allowed me to access and repair a vein just under 1 millimeter in diameter, with clips spaced 4 millimeters apart,” said Dr. Siddiqui. “It required techniques that would be extraordinarily difficult for most micro-neurosurgeons to replicate without robotic assistance, using sutures so small they are barely visible to the naked eye. Based on this excellent initial experience, I have no doubt Symani could be highly effective during a wide range of complex neurosurgical procedures with the development of additional microsurgical tools. In fact, I believe it is ready for superficial temporal to middle cerebral artery bypass surgery today.”

The Symani Surgical System is designed to provide enhanced precision and control for the anastomosis and suturing of microscopic vessels with the thinnest available sutures. With the world’s smallest surgical robotic wrist, called NanoWrist®, Symani enables surgeons to replicate the natural movements of the human hand at the micro scale. It also features motion-scaling technology that reduces the hand’s scale of movement by as much as 20x, giving surgeons more freedom to operate on microscopic anatomy.

Surgeons have leveraged the Symani Surgical System in over 1,000 cases globally and more than two dozen publications highlight positive clinical outcomes. It is designed to help restore quality of life for patients, accelerate the number of surgeons able to push the boundaries of complex procedures for delicate anatomy, and enable hospitals to expand their open surgical programs.

The U.S. Food and Drug Administration (FDA) granted De Novo Classification to the Symani Surgical System in April 2024, making it the only commercially available platform in the U.S. for reconstructive microsurgery. It is available for commercial use in Europe and parts of Asia Pacific.

To learn more about MMI and the Symani Surgical System, visit MMI’s website here: https://mmimicro.com.

About MMI

MMI (Medical Microinstruments, Inc.) is on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. The company was founded in 2015 near Pisa, Italy, and its proprietary Symani® Surgical System combines the world’s smallest wristed microinstruments with tremor-reducing and motion-scaling technologies to address significant unmet patient needs across the globe. This first-of-its-kind surgical robotic platform for open, soft tissue micro-level surgery can help address microvascular repair and lymphatic repair. In Europe and APAC, it also addresses peripheral nerve repair. The Symani System is authorized for use in the U.S. by the FDA and is a CE Marked medical device in Europe. MMI is backed by global investors including Fidelity Management & Research Company, Andera Partners, BioStar, Deerfield Management, Fountain Healthcare Partners, Panakès Partners, RA Capital, Sambatech, and Wellington Partners.

About the Jacobs Institute

The Jacobs Institute is a non-profit organization whose mission is to accelerate the development of next-generation technologies for vascular and neurologic diseases through collisions of physicians, engineers, entrepreneurs, and industry. The JI’s vision is to improve the treatment of vascular and neurologic disease in Western New York and the world, while fostering local economic development. The JI fosters medical collaboration and innovation through partnerships with the University of Buffalo (UB), Kaleida Health, and industry to be a fitting tribute to the work and memory of Lawrence D. Jacobs, MD. Additionally, the JI’s i2R, or Idea to Reality Center, is taking ideas for vascular and neurologic medical devices and moving them through the proof-of-concept process. Finally, the JI also increases physician and industry knowledge of vascular and neurologic diseases through clinical education programs.

Contacts

Media:
Dan Ventresca
Matter Health for MMI
MMI@matternow.com

Investor Relations:
Lisa Croke
Lisa.Croke@mmimicro.com

MMI Builds Global Momentum with Multiple Distribution Agreements and Regulatory Approvals

Expansion includes fastest-growing market for microsurgical procedures and opportunity for considerable advancement, improved patient treatment options

MMI (Medical Microinstruments, Inc.), a robotics company dedicated to increasing treatment options and improving clinical outcomes for patients with complex conditions, today announced milestones across two continents that increase the global reach of the Symani® Surgical System.

The company announced:

• It reached an exclusive distribution agreement with Gunze Medical Limited, a leading developer and manufacturer of medical devices in Japan. The agreement signals a step toward commercializing Symani across Japan, upon regulatory approval, and will eventually enable hospitals there to expand their open surgical programs to include microsurgery and supermicrosurgery procedures.

• The Symani Surgical System has now received regulatory approvals in 35 countries around the world, most recently securing approvals in Hong Kong, Malaysia, New Zealand and Taiwan. They mark Symani’s latest regulatory milestones following the U.S. Food and Drug Administration authorizing the system for commercial use in April.

• It has expanded commercialization efforts in Europe by partnering with the Synektik Group, a leading integrator of innovative medical solutions that covers six countries across Eastern Europe. The agreement marks the next stage in bolstering Synektik’s standing as a top distributor of robotic medical systems in the region.

“The demand for innovative, less invasive, highly precise surgical options is increasing around the world, particularly in Asia, where microsurgery and reconstructive surgery both have long histories,” said Mark Toland, CEO of MMI. “Our recent regulatory approvals in multiple countries, and growing relationships with distributors in key markets, have enabled us to accelerate our timeline for global expansion. Each new milestone represents another step toward expanding patient access to highly advanced microsurgical capabilities around the world.”

The Symani Surgical System uniquely addresses the scale and complexities of microsurgery and supermicrosurgery, such as the anastomosis and suturing of small anatomical structures like blood and lymphatic vessels, during open surgical procedures. By allowing surgeons to replicate the natural movements of the human hand at the micro scale, it can help restore quality of life for more patients, accelerate the number of surgeons able to push the boundaries of complex procedures for delicate anatomy, and enable hospitals to expand their open surgical programs.

“Our partnership with MMI will facilitate the Symani Surgical System’s expansion into Japan,” said Shojiro Matsuda, President of Gunze Medical Limited. “We are deeply committed to expanding patient access to robotic-assisted microsurgery and believe Symani’s proven clinical success will complement our relationships with care provider organizations with expertise in plastic and reconstructive surgery.”

Asia-Pacific represents the fastest growing microsurgery market in the world, and Taiwan specifically is a hub of microsurgical innovation that attracts surgeons from around the globe. MMI has already signed a distributor agreement in the country to support its regulatory approval there and details are being finalized on the heels of the authorization.

“MMI’s mission to expand patient access to highly specialized microsurgical options perfectly aligns with our own as we help to further enable robotic capabilities across Poland and Eastern Europe,” said Cezary Kozanecki, founder and CEO of Synektik. “Symani has introduced a new level of capability and enabled surgeons to perform exceptionally precise procedures that include lymphedema repair, head and neck cancer-related reconstruction, and autologous breast reconstruction. Our health system partners have already expressed significant interest in expanding their open surgery capabilities to include procedures they haven’t been able to previously perform.”

To learn more about MMI and the Symani Surgical System, visit MMI’s website here: https://mmimicro.com.

About MMI

MMI (Medical Microinstruments, Inc.) is on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. The company was founded in 2015 near Pisa, Italy, and its proprietary Symani® Surgical System combines the world’s smallest wristed microinstruments with tremor-reducing and motion-scaling technologies to address significant unmet patient needs across the globe. This first-of-its-kind surgical robotic platform for open, soft tissue micro-level surgery can help address microvascular repair and lymphatic repair. In Europe and APAC, it also addresses peripheral nerve repair. The Symani System is authorized for use in the U.S. by the FDA and is a CE Marked medical device in Europe. MMI is backed by global investors including Fidelity Management & Research Company, Andera Partners, BioStar, Deerfield Management, Fountain Healthcare Partners, Panakès Partners, RA Capital, Sambatech, and Wellington Partners.

Contacts

Media:
Dan Ventresca
Matter Health for MMI
MMI@matternow.com

Investor Relations:
Lisa Croke
Lisa.Croke@mmimicro.com

MMI Receives FDA Authorization to Commercialize Symani® Surgical System in the U.S.

De Novo Classification builds on proven clinical success and expands global access to new category of treatments

MMI (Medical Microinstruments, Inc.), a robotics company dedicated to increasing treatment options and improving clinical outcomes for patients with complex conditions, today announced that its Symani® Surgical System is now commercially available in the United States. The U.S. Food and Drug Administration (FDA) granted De Novo Classification to the robotic system for soft tissue manipulation to perform microsurgery, a highly specialized technique that involves reconnecting tiny vessels to restore blood flow or redirect fluid during reconstruction or repair.

The FDA authorization makes the Symani Surgical System the only commercially available platform in the U.S. for reconstructive microsurgery. The technology is positioned to open the field of microsurgery to new surgeons by quickly developing their skills, as well as to empower skilled microsurgeons to confidently expand into supermicrosurgery, creating a novel category of treatments that the human hand cannot perform without robotic assistance.

“The U.S. is facing a potentially dire shortage of physicians, and that shortage acutely impacts specialized fields of medicine, such as microsurgery,” said Mark Toland, CEO of MMI. “With the authorization from the FDA, our technology will expand its reach to pioneering hospitals in the U.S. It will help those hospitals grow their open surgical programs, expand the number of physicians who can perform these highly complicated procedures, and increase patient access to the most advanced techniques for surgeries in complex disease states, such as lymphedema. Our system will continue to provoke surgeons to challenge their definitions of ‘treatable’ and ‘untreatable’ and empower them to solve cases that have historically been too difficult to treat.”

Specific techniques used in microsurgery include reconnecting small anatomical structures, such as blood and lymphatic vessels, during open surgical procedures. Supermicrosurgery involves reconstruction or repair of even smaller vessels, typically less than 1mm in diameter, and fewer than 600 surgeons worldwide perform supermicrosurgery today.

The Symani Surgical System provides advanced solutions for a range of open surgeries, including post-mastectomy breast cancer reconstruction, extremity reconstruction using free tissue transfer, and lymphatic system repair.

“By making open surgery less invasive and more precise, we can treat more conditions and offer robotic-assisted surgical options to patients that simply do not exist today,” said Dr. L. Scott Levin, co-CMO of MMI. “Within the next five years, this expanded portfolio of addressable open surgical procedures is expected to exceed the number of eligible laparoscopic, or minimally invasive, procedures that leverage robotic assistance. The authorization from the FDA helps to solve a critical unmet need and will help surgeons perform a new category of complex open surgeries enabled by transformative technology.”

The Symani Surgical System offers surgeons entirely new capabilities because it features the world’s smallest surgical robotic wrist, called NanoWrist®. The unique design enables surgeons to replicate the natural movements of the human hand at the micro scale, which encourages a flatter learning curve in the training process. The articulated wrist features seven degrees of freedom that match the human wrist, tremor filtration and motion scaling, ultimately increasing precision and control.

Surgeons have leveraged the Symani Surgical System in nearly 1,000 clinical cases in the European Union and in thousands of preclinical cases around the world. The Symani Surgical System is available for commercial use in Europe and parts of Asia Pacific. MMI plans to immediately launch the technology in the U.S.

To learn more about MMI and the Symani Surgical System, visit MMI’s website here: https://mmimicro.com.

About MMI

MMI (Medical Microinstruments, Inc.) is on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. The company was founded in 2015 near Pisa, Italy, and its proprietary Symani® Surgical System combines the world’s smallest wristed microinstruments with tremor-reducing and motion-scaling technologies to address significant unmet patient needs across the globe. This first-of-its-kind surgical robotic platform for open, soft tissue micro-level surgery can help address microvascular repair and lymphatic repair. In Europe, it also addresses peripheral nerve repair. The Symani System is authorized for use in the U.S. by the FDA and is a CE Marked medical device in Europe. MMI is backed by global investors including Fidelity Management & Research Company, Andera Partners, BioS

MMI Raises $110 Million in Series C Financing

Largest ever investment in microsurgery will further MMI’s mission to transform open surgery with robotic technology

MMI (Medical Microinstruments, Inc.), a robotics company dedicated to increasing treatment options and improving clinical outcomes for patients with complex conditions, today announced that it has raised $110 million in Series C financing. The round, led by Fidelity Management & Research Company, marks the largest ever investment in microsurgery innovation.

The funds will support commercialization of the Symani® Surgical System in high-growth markets and continued investment in studies that generate clinical evidence and enable indication expansion. Investments will also accelerate advanced technology capabilities and enable MMI to scale its operational capabilities globally.

MMI and its existing investors, all of whom contributed to the Series C financing, see considerable opportunity for rapid growth. The company projects the market for eligible robotic microsurgical procedures will grow from 3 million to 22 million annually by 2028, driven primarily by technological advancements and indication expansion.

“Against a backdrop of plateauing investments in medical robotics, this support builds on our confidence in a new, less invasive solution for open surgery, a significant market that can benefit from the smallest wristed microinstruments,” said Mark Toland, CEO of MMI. “Our Symani Surgical System is uniquely positioned to expand patient access to care by accelerating the number of surgeons able to perform complex, delicate procedures. With the support of our investors, we will continue to advance our technology through a growing body of clinical evidence and expanded hospital partnerships.”

The Symani Surgical System is a first-of-its-kind robotic technology that uniquely addresses the scale and complexities of microsurgery and supermicrosurgery. By allowing surgeons to replicate the natural movements of the human hand at the micro scale, it can expand treatment options for patients in need of soft tissue, open surgical procedures, such as free flap reconstructions, lymphatic surgery, and trauma replantations. It is designed to help restore quality of life for more patients, accelerate the number of surgeons able to push the boundaries of complex procedures for delicate anatomy, and enable hospitals to expand their open surgical programs.

MMI has raised over $200 million in funding to date. In 2022, it closed a Series B financing round to propel growth. The funding was allocated to help expand indications and support ongoing commercialization efforts for the Symani Surgical System in Europe, where it received CE mark in 2019, accelerate plans to commercialize in the U.S. and Asia-Pacific, and advance clinical research.

To learn more about MMI and the Symani Surgical System, visit MMI’s website here: https://mmimicro.com.

About MMI

MMI (Medical Microinstruments, Inc.) is on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. The company was founded in 2015 near Pisa, Italy, and its proprietary Symani® Surgical System combines the world’s smallest wristed microinstruments with tremor-reducing and motion-scaling technologies to address significant unmet patient needs across the globe. This first-of-its-kind surgical robotic platform for open, soft tissue micro-level surgery can help address microvascular repair, lymphatic repair, and peripheral nerve repair. The Symani System is CE Marked for commercial use in Europe. In the United States, the system is not approved or cleared for commercial use. MMI is backed by global investors including Fidelity Management & Research Company, Andera Partners, BioStar, Deerfield Management, Fountain Healthcare Partners, Panakès Partners, RA Capital, Sambatech, and Wellington Partners.

MMI Expands Global Footprint with Entry into Asia Pacific Market

Partnerships with Device Technologies and TRM Korea will strengthen Symani® Surgical System’s entrance into the world’s fastest-growing surgical robotics market.

MMI, (Medical Microinstruments, Inc.), a robotics company dedicated to increasing treatment options and improving clinical outcomes for patients with complex conditions, today announced that it will continue its global momentum with two distribution agreements covering nearly a dozen countries in the Asia Pacific (APAC) region. The first partnership, with Device Technologies, will help to introduce the Symani Surgical System to Hong Kong, Singapore, Vietnam, Malaysia, Indonesia, Thailand, Philippines, Macau, and New Zealand, upon applicable regulatory approvals, as well as Australia, where it recently received approval from the Therapeutic Goods Administration (TGA). The other partnership, with TRM Korea, will facilitate the system’s entry into South Korea upon regulatory approval and will introduce microsurgical robotic technology to interested surgeons and hospitals.

The Symani Surgical System is a first-of-its-kind robotic technology that uniquely addresses the scale and complexities of microsurgery and supermicrosurgery. By allowing surgeons to replicate the natural movements of the human hand at the micro scale, it can expand treatment options for patients in need of soft tissue open surgical procedures, such as free flap reconstructions, lymphatic surgery, and trauma reconstructions. It is designed to help restore quality of life for more patients, accelerate the number of surgeons able to push the boundaries of complex procedures for delicate anatomy, and enable hospitals to expand their open surgical programs.

“Through our new partnerships in Asia Pacific, we have established roots that will ultimately help us expand patient access to robotic microsurgical and supermicrosurgical capability in a region of the world with clear demand for the technology,” said Matt Lemay, VP of Asia Pacific of MMI. “Surgeons from the APAC region have long been at the forefront of innovation in microsurgery, and we look forward to helping further those capabilities with the Symani Surgical System. As we advance our mission of increasing treatment options for patients with complex conditions, we are enthusiastic about our global progress and look forward to continuing our momentum in APAC and beyond.”

Device Technologies has provided healthcare professionals access to innovative, high quality medical devices, including leading robotics solutions, for over 30 years. They will open a new research and education center for robotic microsurgery with a premier medical institution as part of their partnership with MMI. The center will represent the first site in Central Asia where interested surgeons can learn more about the system.

“MMI and the Symani Surgical System are well aligned with our core mission to provide physicians and healthcare facilities with solutions that can drive improved patient outcomes,” said Heath Priestly, Managing Director at Device Technologies. “Originating in Australia, we have broadened our presence throughout the Asia Pacific region, establishing expertise and strong connections. We are eager to use our footprint to support MMI’s health system partnerships across the region and further increase patient access to sophisticated surgical techniques for complex conditions.”

TRM is the largest microsurgery company in South Korea and a pioneer in the medical technology and innovation space. They are collaborating with a world-renowned medical institution to open their own education center where surgeons will have the opportunity for informational sessions and hands-on learning about the Symani Surgical System. To learn more about MMI, visit https://mmimicro.com.

About MMI

MMI (Medical Microinstruments, Inc.) is on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. The company was founded in 2015 near Pisa, Italy, and its proprietary Symani® Surgical System combines the world’s smallest wristed microinstruments with tremor-reducing and motion-scaling technologies to address significant unmet patient needs across the globe. This first-of-its-kind surgical robotic platform for open, soft tissue micro-level surgery can help address microvascular repair, lymphatic repair, and peripheral nerve repair. The Symani System is CE Marked for commercial use in Europe. In the United States, the system is not approved or cleared for commercial use. MMI is backed by international medtech investors including Andera Partners, BioStar, Deerfield Management, Fountain Healthcare Partners, Panakès Partners, RA Capital, Sambatech, and Wellington Partners.

MMI’s Symani® Robotic Surgical System Surpasses 500 Clinical Procedures

• Milestone case performed at HUS Helsinki University Hospital demonstrates MMI’s continued momentum in the soft tissue open surgery field

MMI, (Medical Microinstruments, Inc.), a robotics company dedicated to increasing treatment options and improving clinical outcomes for patients with complex conditions, today announced the successful completion of over 500 in-human surgeries with the Symani® Surgical System in the European Union. The Symani Surgical System is a first-of-its kind robotic technology that uniquely addresses the scale and complexities of microsurgery and supermicrosurgery. It aims to restore quality of life for more patients, accelerate the number of surgeons able to push the boundaries of complex procedures for delicate anatomy, and enable hospitals to expand their open surgical programs.

Millions of patients today with complex conditions lack access to treatment options that optimize outcomes due to human physical limitations on the microsurgical scale and a lack of specialists able to perform surgery on tiny, delicate anatomy. The Symani Surgical System is poised to help. It is a robotic platform that enables expanded options for patients in need of soft tissue open surgical procedures, such as free flap reconstructions, lymphatic surgery, trauma reconstructions, and peripheral nerve repairs. Since the first in-human cases in October 2020, the system has been used in over 500 procedures, rapidly increasing patient access to surgical treatment options as surgeons become comfortable using the technology.

“We believe that open surgery is long overdue for technological advancement. This major milestone for the Symani Surgical System is a testament to how robotics can elevate the standard of care by pushing the boundaries of complexity,” said Mark Toland, CEO of MMI. “People with hard-to-treat conditions deserve options that can give them a better quality of life, and we hope that by expanding access to microsurgical and supermicrosurgical procedures, we’re able to drive that initiative forward.”

The Symani Surgical System’s unique capabilities in open microsurgery are a result of its proprietary NanoWrist® instruments, which feature the world’s smallest surgical robotic wrist. This enables surgeons to replicate the natural movements of the human hand at the micro scale with seven degrees of freedom, tremor filtration, and motion scaling, ultimately increasing precision and control.

The 500th procedure was a lymphatic repair performed by Sinikka Suominen, PhD, MD, plastic surgeon at the HUS Helsinki University Hospital in Finland. HUS Helsinki University Hospital is one of the largest University Hospitals in Europe and is also a European and International Microsurgery Centre of Reference. In 2023, it was ranked No. 39 on Newsweek’s list of the World’s Best Hospitals. Of the 500 procedures completed to date, approximately 75 percent have been free flap surgeries, and 16 percent have been lymphatic repairs. The remaining 9 percent have consisted of other procedures such as peripheral nerve repairs and extremity replantation surgeries.

“Our hospital is using the Symani Surgical System across multiple procedure types, such as lymphatic repair and head and neck cancer-related reconstructive surgery, and I’ve experienced notable changes in the accuracy, stability, and reliability of my suture placement during lymphatic procedures,” said Dr. Suominen. “These are quality of life surgeries that enable patients to return to work or simply resume their normal daily activities. Lymphedema at its worst is a disabling condition, and advanced microsurgical procedures can give patients hope for a better quality of life. I’m proud to have completed this milestone procedure and look forward to many more opportunities to help patients through open, robotic microsurgery.”

To learn more about MMI, visit http://mmimicro.com.

About MMI

MMI (Medical Microinstruments, Inc.) is on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. The company was founded in 2015 near Pisa, Italy, and its proprietary Symani® Surgical System combines the world’s smallest wristed microinstruments with tremor-reducing and motion-scaling technologies to address significant unmet patient needs across the globe. This first-of-its-kind surgical robotic platform for open, soft tissue micro-level surgery can help address microvascular repair, lymphatic repair, and peripheral nerve repair. The Symani System is CE Marked for commercial use in Europe. In the United States, the system is not approved or cleared for commercial use. MMI is backed by international medtech investors including Andera Partners, BioStar, Deerfield Management, Fountain Healthcare Partners, Panakès Partners, RA Capital, Sambatech, and Wellington Partners.

Contacts

Dan Ventresca
Matter Health for MMI
mmi@matternow.com

Medical Microinstruments Secures $75M to Advance Robotic Microsurgery

Series B financing will accelerate clinical trials and global commercialization of the company’s Symani® Surgical System

Medical Microinstruments, Inc. (MMI), a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery, today announced it has raised $75 million in Series B financing. Deerfield Management led the round with participation from new investors, RA Capital Management and Biostar Capital, as well as existing investors, Andera Partners, Fountain Healthcare Partners, Panakès Partners and Sambatech. The company also announced the addition of three new members to its board of directors.

In addition, the company announced its corporate redomicile from Italy to the United States. The recently opened Center of Excellence facility in Pisa, Italy, with nearly 100 employees will continue to be the hub of the company’s research and development, manufacturing, and other business activities.

Proceeds from this financing round and the company’s planned U.S. presence will launch MMI into its next stage of growth as it continues its mission to improve the quality of patient care by pushing the boundaries of microsurgery. The company seeks to expand indications and support ongoing commercialization efforts for the Symani® Surgical System in Europe where it received CE mark in 2019. MMI also intends to accelerate plans to commercialize in the U.S. and Asia-Pacific, as well as advance clinical research including securing an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration to conduct a pivotal study. The Symani System was developed specifically to address the challenges of microsurgery and is the only system that offers NanoWrist® Instruments designed to improve a surgeon’s ability to access and suture small, delicate anatomy.

“This financing round, coupled with our commitment to access the U.S. market and the addition of visionary leaders to our board, is an exciting moment for the surgical robotics space,” said Mark Toland, CEO of MMI. “We’re pleased to have bridged the Atlantic with premier U.S. life science investors, and existing European investors, who share our same vision of bringing microsurgical robotics to the world.”

The company’s new board members are Andrew ElBardissi, MD, Tess Cameron and Arturo Baroncelli. Dr. ElBardissi is a partner at Deerfield Management, with extensive experience serving as a board member for innovative healthcare companies. Ms. Cameron serves as principal for RA Capital Management and currently sits on the boards of Avilar Therapeutics and Nodexus Inc. Baroncelli previously worked as a robotics business development manager for Comau and will represent MMI’s founders on the board.

“We are thrilled to add further depth and experience to the MMI Board and look forward to working with our new board members to build the robotic microsurgical space,” said Andrew Cleeland, Chairman of the Board for MMI.

“The MMI technology is one of the most significant transformational advancements in surgical robotics that we have seen,” said Dr. ElBardissi. “Having the world’s smallest wristed instruments opens up the field of ‘micro’ robotics to a completely new level of treatment spanning microsurgery for cancer, trauma, orthopedic, pediatric, and one day, neurosurgery patients. Symani will be the future of how microsurgery is performed worldwide.”

“Robotic microsurgery has enormous potential to both improve the standard of care for patients and help surgeons manage procedures that require delicate precision,” said Ms. Cameron. “I look forward to supporting MMI and its world-class team as it begins this exciting chapter.”

The Symani Surgical System is designed to improve a surgeon’s ability to repair anatomical structures such as veins, arteries, nerves and lymphatic vessels as small as 0.3 mm in diameter. The platform provides motion scaling and tremor reduction to allow precise micromovements. Its NanoWrist technology is the world’s smallest wristed instrumentation and is intended to improve a surgeon’s natural dexterity and range of motion beyond the capability of the human hand.

About Medical Microinstruments, Inc.

Medical Microinstruments, Inc. (MMI) was founded in 2015 near Pisa, Italy to enhance surgical performance through the development of a robotic system that enables surgeons to achieve better outcomes in microsurgery. The Symani Surgical System combines proprietary innovations including the world’s smallest wristed microinstruments as well as tremor-reducing and motion-scaling technologies. Together, these powerful capabilities allow more surgeons to successfully perform microsurgery while expanding the field of supermicrosurgery. MMI is backed by international medtech investors including Andera Partners, BioStar, Deerfield Management, Fountain Healthcare Partners, Panakès Partners, RA Capital and Sambatech.

Media Contact:

Sarah Lundberg
Health+Commerce
sarahlundberg@healthandcommerce.com

Medical Microinstruments Launches New Simulator for Robotic Microsurgery

Symani Simulator to accelerate the expansion and adoption of robotic microsurgery

Medical Microinstruments (MMI) SpA, a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery, today announced the launch of its Symani Surgical System Simulator developed by VirtaMed. The simulator will improve, expand, and digitize the pathways for Symani training as surgeons prepare to expand their microsurgical skills through robotics.

“It was a priority for our company to offer our surgeons a simulation solution so they can practice robotic microsurgery in a more convenient way,” said Mark Toland, CEO of MMI SpA. “By training on the simulator, surgeons will be even more prepared for their first Symani patient or for a challenging case.”

“We were looking for a way to provide surgeons with a Symani experience without needing to transport the system,” said Jamie Milas, VP of Marketing at MMI SpA. “We selected VirtaMed as our trusted partner because of their shared passion for improving patient care and because we knew that they could develop a fully customized simulator that would emulate our device and showcase the advantages of Symani microsurgery.”

VirtaMed was incorporated in 2007 and is a world leader in surgical training solutions and data-driven medical education. VirtaMed develops world-class and educationally relevant virtual reality simulators for various medical disciplines such as orthopedics, obstetrics, gynecology, urology and laparoscopy. The VirtaMed LaparoSTM offers an experience that looks and feels real to the users, including correct physical behavior of internal organs and true to life interactions of surgical tools with those organs.

“We’re thrilled to partner with MMI to address this new frontier of robotic surgery,” said Stefan Tuchschmid, Co- CEO at VirtaMed. “MMI’s technology provides tremendous value for the surgical community and the patients they serve. We’re proud that our collaboration has led to a simulator that’s so realistic that surgeons can immediately begin suturing on Symani after just a few minutes of practice on the simulator.”

Incorporating simulation will also accelerate MMI’s product development process by enabling new solutions to be tested in a virtual environment for efficacy and usability.

MMI’s Symani Surgical System is the only robot dedicated to microsurgery that offers wristed instruments designed to improve a surgeon’s ability to access and suture small, delicate anatomy. Its platform provides motion scaling and tremor reduction to allow surgeons to make precise micro-movements. With Symani, surgeons can perform suturing, ligation, anastomoses and coaptations.

MMI will exhibit at the European Association of Plastic Surgeons, May 26-28 in Naples, Italy and at the World Society for Reconstructive Microsurgery Congress, June 1-4, in Cancun, Mexico. Demonstrations of the Symani Simulator and Symani Surgical System will be available at the MMI booth.

About MMI SpA

Medical Microinstruments S.p.A. (MMI) was founded in 2015 near Pisa, Italy to enhance surgical performance through the development of a robotic system that enables surgeons to achieve better outcomes in microsurgery. The Symani Surgical System combines proprietary innovations including the world’s smallest wristed microinstruments as well as tremor-reducing and motion-scaling technologies. Together, these powerful capabilities allow more surgeons to successfully perform microsurgery while expanding the field of supermicrosurgery. MMI is backed by international medtech investors including Andera Partners, Panakes Partners, Fountain Healthcare Partners and Sambatech.

About VirtaMed

VirtaMed believes medical education is powerfully delivered through data-driven simulation solutions. Since 2007, we have developed the leading solutions for training outside the operating room because we believe healthcare professionals should never have to perform a procedure for the first time on a patient. VirtaMed’s simulators provide the most realistic and cost-effective training available for laparoscopic surgeons.

Media Contact:

Sarah Lundberg
Health+Commerce
sarahlundberg@healthandcommerce.com

Media Contact VirtaMed:

Alex Gunderson
Padilla
Alex.Gunderson@padillaco.com

Medical Microinstruments Announces Major Expansion in Pisa, Italy to Support Growth

New facility will expedite the development and production of MMI’s Symani® robotic microsurgical system

Medical Microinstruments (MMI) SpA, a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery, today announced the grand opening of its new facility in Pisa, Italy. MMI consolidated locations throughout the Pisa area into a 3,000m2 singular site designed to accommodate company growth. The state-of-the-art facility will serve as the global ‘Center of Excellence’ for microsurgical surgical robotics, encompassing development, manufacturing, and administration.

“Our new facility in Pisa marks the beginning of an exciting new era for MMI,” said Mark Toland, CEO of MMI. “This new space reflects our focus on innovation, collaboration and growth. The expanded manufacturing center will ensure that we are prepared to address new markets and reach more patients with our Symani System and NanoWrist® Instruments.”

The building was fully renovated over 12 months and will serve as the primary office for employees, including a large team of R&D professionals with access to five new advanced R&D labs.

“Working all together in the new facility improves communication and disruptive innovation which is ideal for our research, engineering and clinical efforts,” said Massimiliano Simi, VP of R&D at MMI. “With our new laboratories, we are poised to continue the rapid development and high-quality product design our surgeon’s have come to expect.”

The space was designed to promote teamwork and accommodate the company’s fast growth with 40 additional hires expected by the end of 2022. The 900m2 state-of-the-art manufacturing center includes a clean room and with the capacity to meet the global demand for at least the next 5 years.

“Our cutting-edge facility touts the most advanced manufacturing technologies and production processes, many of which we have patented,” commented Giancarlo Testaverde, VP of Operations at MMI. “We are equipped and ready to meet the increased demands as we expand our installed base and address new markets.”

The Symani System is the only robotic surgical system that offers wristed microinstruments designed to improve a surgeon’s ability to access and suture small, delicate anatomy. The platform provides motion scaling and tremor reduction to allow surgeons to perform precise micro-movements. With Symani, surgeons can perform suturing, anastomoses and coaptations which are required during many complex microsurgical procedures.

"I'm pleased to welcome MMI, an innovative company that fully embodies the entrepreneurial spirit of Tuscany, to its new office in Pisa," said Eugenio Giani, President of Tuscany. "The life sciences industry is growing in our region, and we're eager to support the future growth of the company, especially through our ‘Invest In Tuscany’ office."

About MMI SpA

Medical Microinstruments S.p.A. (MMI) was founded in 2015 near Pisa, Italy to enhance surgical performance through the development of a robotic system that enables surgeons to achieve better outcomes in microsurgery. The Symani Surgical System combines proprietary innovations including the world’s smallest wristed microinstruments as well as tremor-reducing and motion-scaling technologies. Together, these powerful capabilities allow more surgeons to successfully perform microsurgery while expanding the field of supermicrosurgery. MMI is backed by international medtech investors including Andera Partners, Panakes Partners, Fountain Healthcare Partners and Sambatech.

Media Contact:
Sarah Lundberg
Health+Commerce
sarahlundberg@healthandcommerce.com

Lymphovenous Anastomosis and Lymph Node Transfer Performed with Medical Microinstruments’ Symani® Surgical System at the Renowned University Hospital Zurich

System acquired to enhance hospital’s lymphatic’s program

Medical Microinstruments (MMI) SpA, a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery, announced today the University Hospital Zurich (USZ), Division of Plastic and Hand Surgery, successfully completed its first case using the Symani® Surgical System. Prof. Nicole Lindenblatt, M.D. performed a lymph node transfer and lymphovenous anastomosis (LVA), a novel and challenging supermicrosurgical procedure intended to improve the patient's lymphedema by allowing outflow of lymphatic fluid through residual lymphatic channels.

“Empowering surgeons with additional precision and dexterity through robotics has tremendous potential to evolve how effectively we treat a range of conditions,” said Mark Toland, Chief Executive Officer of MMI. “Prof. Lindenblatt’s procedure marks a milestone in improving treatment for lymphedema, a disease state with lengthy and burdensome effects on patients. As additional hospitals adopt the Symani Surgical System, supermicrosurgical techniques will offer patients new treatment possibilities that are too small to effectively address by hand.”

The University Hospital Zurich, the No. 2-ranked hospital in Switzerland and No. 12 hospital in the world according to a recent poll in Newsweek, installed the Symani Surgical System in July to enhance its lymphatic surgery program. About 250 million people in the world suffer from some form of lymphedema, which is characterized by excess lymphatic fluid causing swelling in the arms or legs.

The Symani Surgical System is designed to repair small anatomical structures such as blood vessels, nerves and lymphatic ducts that may be as small as 0.3mm in diameter. The Symani Surgical System has been shown to reduce the occurrence of thrombosis by 50 percent in preclinical studies by mitigating hand tremor and scaling movements up to 20X. The Symani Surgical System received CE Mark in 2019 and is intended for free-flap reconstructions, replantations, congenital malformations, peripheral nerve repairs, lymphatic surgeries and more.

To learn more about MMI and the Symani Surgical System, please visit: www.mmimicro.com.

About MMI

Medical Microinstruments S.p.A. (MMI) was founded in 2015 near Pisa, Italy to enhance surgical performance through the development of a robotic system that enables surgeons to achieve better outcomes in microsurgery. The Symani Surgical System combines proprietary innovations including the world’s smallest wristed microinstruments as well as tremor-reducing and motion-scaling technologies. Together, these powerful capabilities allow more surgeons to successfully perform microsurgery while expanding the field of supermicrosurgery. MMI is backed by international medtech investors including Andera Partners, Panakes Partners, Fountain Healthcare Partners and Sambatech.

About University Hospital Zurich

The University Hospital Zurich (USZ) is internationally renowned for its achievements in university medicine, nursing, research and teaching. More than 42,000 inpatients and over 600,000 outpatient consultations per year testify to the great trust placed in the USZ and its approximately 8,500 employees. Thanks to the interdisciplinary cooperation of more than 40 clinics and institutes as well as the proximity to the University and ETH Zurich, the University Hospital Zurich offers its patients the broad experience of its specialists and up-to-date therapies.

Media Contact:

Matter Health for MMI
Dan Ventresca
617-874-5488
mmi@matternow.com
www.matternow.com

Medical Microinstruments Announces First Commercial Installation of the Symani® Surgical System

University Hospital Salzburg solidifies standing as leader in microsurgery by being first to commit to robotic-assisted platform

Medical Microinstruments (MMI) SpA, a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery, announced today the University Hospital Salzburg, part of the Salzburg State Hospitals (SALK), is the world’s first hospital to implement the Symani® Surgical System for commercial use in its robotic microsurgery programs. A leading hospital in the DACH region and one of the largest hospitals in Austria, SALK will specifically leverage Symani to further enhance its capabilities in oral and maxillofacial surgery.

“University Hospital Salzburg has demonstrated a sincere desire to further improve patient care through robotic-assisted surgeries and is an ideal partner for launching our Symani Surgical System commercially,” said Mark Toland, Chief Executive Officer of MMI. “Innovation in microsurgery has been lacking over the last decades but it is clearly an ideal field for surgical robotics as the procedures are complex and require extreme precision. SALK is a visionary teaching institution that is keen to apply technology to microsurgical techniques and unlock the possibilities of supermicrosurgery with Symani.”

The Symani Surgical System and its NanoWrist Instrumentation were designed to augment a physician’s capabilities during microsurgical procedures by reducing tremor and scaling movements up to 20X. It can repair anatomical structures such as blood vessels, nerves and lymphatics that may be as small as 0.2mm in diameter. Specific procedures that may benefit from enhanced precision include free-flap reconstructions, replantations, congenital malformations, peripheral nerve repairs and lymphatic surgeries. Lymphedema marks one disease state with an acute need for improved treatment options, as it impacts nearly 250 million people worldwide who often suffer from long periods of treatment with limited effectiveness.

“SALK’s mission is to offer patients the highest level of care available today, which is why pioneering robotic microsurgery is so important to us,” said Prof. Alexander Gaggl, M.D., Department of Oral and Maxillofacial Surgery at the University Hospital Salzburg. “From the moment we evaluated the Symani Surgical System, we knew that robotic microsurgery was the future, and we began to imagine how we could expand our capabilities through the system and its NanoWrist instruments.”

SALK intends to participate in MMI’s post-market study to validate the intended clinical benefits of the Symani Surgical System.

To learn more about MMI and the Symani Surgical System, visit www.mmimicro.com.

About MMI

Medical Microinstruments S.p.A. (MMI) was founded in 2015 near Pisa, Italy to enhance surgical performance through the development of a robotic system that enables surgeons to achieve better outcomes in microsurgery. The Symani Surgical System combines proprietary innovations including the world’s smallest wristed microinstruments as well as tremor-reducing and motion-scaling technologies. Together, these powerful capabilities allow more surgeons to successfully perform microsurgery while expanding the field of supermicrosurgery. MMI is backed by international medtech investors including Andera Partners, Panakes Partners, Fountain Healthcare Partners and Sambatech.

About University Hospital Salzburg

The Salzburg State Hospitals are the leading health care provider and employer in the State of Salzburg. The 6,570 employees treat 83,700 in-patients and 9,300 day-patients every year. The Salzburg State Hospital Group manages four hospitals: the University Hospital Salzburg in the City of Salzburg and the State Hospitals in Hallein, St. Veit and Tamsweg.

Contacts

Media:
Matter Health for MMI
Dan Ventresca
617-874-5488
mmi@matternow.com
www.matternow.com

Medical Microinstruments’ Symani Surgical System Saves Patient’s Arm from Amputation

Highly complex, innovative reconstruction procedure part of post-market study

Medical Microinstruments (MMI) SpA, a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery, announced today that MMI’s Symani  Surgical System was successfully used at Careggi University Hospital Florence by Prof. Marco Innocenti and his team in a complex, post-traumatic limb reconstruction that saved a patient’s arm from amputation. The case is the first enrolled patient in MMI’s post-market study.

Prof. Marco Innocenti, M.D., the head of reconstructive surgery and microsurgery at Careggi University Hospital in Florence, performed the procedure which involved a young adult who suffered a motorcycle accident. After eight months of unsuccessful surgeries and bone fixation attempts, the patient received a recommendation for amputation. Dr. Innocenti was made aware of the case and determined the patient was a candidate for a free-flap reconstruction, which involved transferring a piece of bone and its vessels from the lower leg to the patient’s forearm. The robotic-assisted procedure successfully restored blood flow to the area despite severe damage and extensive scar tissue inside the arm.

“Robotic-assisted technology is a revolutionary tool for microsurgery, because it allows physicians to complete procedures that are difficult or impossible with the human hand,” said Dr. Innocenti. “By increasing our precision, we can reconnect submillimeter vessels and nerves that enable reconstruction even after severe trauma. I am confident our post-market study will show significant advantages to improving patient outcomes, as the patient in the motorcycle accident would have lost her arm without robotic-assisted microsurgery.”

The patient marked the first enrolled in the post-market study. It was also the first time Dr. Innocenti performed a free-flap reconstruction with the fibula bone using the Symani Surgical System.

“By evolving surgical intervention from a manual process to one that leverages robotic technology, we can open the door to procedures that have never been done before,” said Mark Toland, chief executive officer of MMI. “Dr. Innocenti’s accomplishment in this case is an extremely exciting piece of validation for our technology that will contribute to our data collection for our growing global regulatory strategy.”

The Symani Surgical System received CE Mark in 2019 and can enhance free-flap reconstructions, replantations, congenital malformations, peripheral nerve repairs and lymphatic surgeries. The platform minimizes hand tremor and scales physician movements (7-20x), reducing the occurrence of thrombosis by 50 percent in preclinical studies. Its NanoWrist  instruments are the world's smallest wristed surgical instrumentation and create seven degrees of freedom for optimal dexterity inside of minimally invasive incisions.

The MMI post-market study at the University of Florence Careggi Hospital is registered at www.clinicaltrials.gov. To learn more about MMI and the Symani Surgical System, please visit: www.mmimicro.com.

About MMI

Medical Microinstruments S.p.A. (MMI) was founded in 2015 near Pisa, Italy to enhance surgical performance through the development of a robotic system that enables surgeons to achieve better outcomes in microsurgery. The Symani Surgical System combines proprietary innovations including the world’s smallest wristed microinstruments as well as tremor-reducing and motion-scaling technologies. Together, these powerful capabilities allow more surgeons to successfully perform microsurgery while expanding the field of supermicrosurgery. MMI is backed by international medtech investors including Andera Partners, Panakes Partners, Fountain Healthcare Partners and Sambatech.

###

For more information, contact:

Matter for MMI
Dan Ventresca
617-874-5488

Medical Microinstruments Appoints Healthcare Industry Veteran Mark Toland as Chief Executive Officer

Toland joins Andrew Cleeland (Chairman of the Board, MMI) in developing the field of robotic-assisted microsurgery

CALCI, Italy – Medical Microinstruments (MMI) SpA, a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery, announced today the hiring of Mark Toland as Chief Executive Officer. He brings more than 25 years of experience in the medical device industry and most recently served as President and CEO of Corindus, a vascular robotics company that Siemens Healthineers acquired for $1.1 billion in 2019. Following the CE mark of MMI’s Symani Surgical System® in 2019 and successfully completing the first human use cases in 2020, Toland will drive the company’s strategic direction from the developmental stage to broad commercialization.

“There is a tremendous need across healthcare to evolve treatment paradigms from a predominantly manual model to one that leverages robotic technology, data integration and AI to improve patient outcomes,” said Toland. “The Symani Surgical System offers an unprecedented level of precision for microsurgical procedures that has the potential to significantly impact patient outcomes in very complex procedures. I look forward to helping the company realize that potential and working with a very talented and growing team at MMI.”

The Symani Surgical System was used to successfully complete four first-in-human surgical procedures in Florence, Italy. The cases included one post-oncological reconstruction of the pharynx and three complex, post-traumatic lower limb reconstructions, demonstrating the combined benefits of tremor reduction and motion scaling (7-20x) with the system’s NanoWrist® instruments, the world's smallest wristed surgical instrumentation. The system offers seven degrees of freedom and dexterity beyond the reach of human hands to enhance free-flap reconstructions, replantations, congenital malformations, peripheral nerve repairs and lymphatic surgery, which represent over one million combined procedures annually in the U.S. and Europe.

“Mark’s extensive experience in the medical device industry and particularly in the field of robotics will play a pivotal role in MMI’s continued growth and impact on microsurgery,” said Andrew Cleeland, the chairman of MMI’s Board of Directors. “We look forward to empowering surgeons around the world with the most advanced technology that will make highly complex procedures more reproducible and new procedures possible.”

Toland joined Corindus in 2016 and transformed the company into the industry leader in vascular robotics with the only approved system for coronary, peripheral and neurovascular indications. Under Toland’s leadership, the company built advanced capabilities in automation and telerobotics, which included the first ever remotely performed heart procedure in the world and transcontinental pre-clinical studies using 5G technology. The Siemens Healthineers acquisition of Corindus for $1.1 billion was the fifth largest medical technology acquisition of 2019. Prior to Corindus, Mark served as Senior Vice President of Boston Scientific, where he built the company’s global solutions business and led all aspects of the U.S. commercial team’s cardiovascular businesses, which represented approximately $4 billion in revenue.

About MMI

Medical Microinstruments S.p.A. (MMI) was founded in 2015 near Pisa, Italy to enhance surgical performance through the development of a robotic system that enables surgeons to achieve better outcomes in microsurgery. The Symani Surgical System combines proprietary innovations including the world’s smallest wristed microinstruments as well as tremor-reducing and motion-scaling technologies. Together, these powerful capabilities allow more surgeons to successfully perform microsurgery while expanding the field of supermicrosurgery.

For more information, contact:

Matter for MMI
Dan Ventresca
617-874-5488
mmi@matternow.com
www.matternow.com

MMI SpA Launches Breakthrough Technology, Advancing Robotic Microsurgery with the World’s Smallest Wristed Surgical Instruments

First Procedures Performed with the Symani Surgical System

MMI SpA, an Italian company dedicated to improving clinical outcomes for patients undergoing microsurgery, announced today the CE Mark, launch and first human use of its Symani® Surgical System in Europe for open microsurgical procedures. The first four robotic surgeries were successfully performed in Florence, Italy, including three complex, post-traumatic lower limb reconstructions as well as a post-oncological reconstruction of the pharynx.

“There is a clear demand for robotics in microsurgery as the limits of the human hand have already been reached. We founded MMI to develop a robotic system designed for and with microsurgeons that will improve outcomes and address unmet patient needs, particularly through supermicrosurgery techniques which are required for lymphatic and other extremely delicate procedures. We are pleased to be at the forefront of a new era in robotic surgery as we launch our Symani System in Europe,” said Giuseppe Maria Prisco, co-founder and CEO of MMI.

The Symani Surgical System combines the benefits of tremor reduction and motion scaling (7-20x) with the world’s smallest wristed instrumentation, offering seven degrees of freedom and dexterity beyond the reach of human hands. The system’s NanoWrist® instruments are designed to overcome the challenges of free-flap reconstructions, replantations, congenital malformations, peripheral nerve repairs and lymphatic surgery, which together represent over one million procedures annually in the U.S. and Europe alone.

“Microsurgery and supermicrosurgery – as a tool, technique and discipline – continue to evolve. The use of robotics holds great promise to advance the specialty of microsurgery and improve care for patients affected by trauma, cancer, congenital malformations and even chronic conditions such as lymphedema,” commented L. Scott Levin, MD, FACS, FAOA, Chair of the Department of Orthopaedic Surgery, Professor of the Plastic Surgery Division at the University of Pennsylvania School of Medicine.

“We are proud to bring this innovation to European patients and look forward to enabling surgeons worldwide to address challenging procedures on extremely small anatomy with increased precision, reproducibility and efficiency,” said Hannah Teichmann, co-founder and Vice President of Clinical Development of MMI.

About MMI Medical Microinstruments S.p.A.

(MMI) was founded in 2015 near Pisa, Italy to enhance surgical performance through the development of a robotic system that enables surgeons to achieve better outcomes in microsurgery. The Symani Surgical System combines proprietary innovations including the world’s smallest wristed microinstruments as well as tremor-reducing and motion scaling technologies. Together, these powerful capabilities allow more surgeons to perform microsurgery while expanding the field of supermicrosurgery. MMI is backed by international medtech investors including Andera Partners, Panakes Partners, Fountain Healthcare Partners and Sambatech.

Dr. Levin serves as a medical advisor to the company and has received financial compensation from Medical Microinstruments S.p.A.

The MMI system for robotic microsurgery is currently only commercially available in the European Economic Area. www.mmimicro.com